Under a new CEO, German CDMO Vibalogics bets $150M and 110,000 square feet on the gene therapy revolution
Vibalogics started out 18 years ago making vaccines for chickens. Now they’re looking to drive the gene and cell therapy revolution — and make a few Covid-19 shots on the way.
On Wednesday, the German CDMO announced they’re investing $150 million into a 110,000 square foot virus and viral vector manufacturing facility in Boston, joining a wave of companies trying to build the infrastructure that can one day mass produce the hundreds of gene and cell therapies now in biotech and Big Pharma pipelines across the globe.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.